$PVLA News

Palvella Therapeutics Completes Pre-NDA Meeting With FDA For QTORIN 3.9% Rapamycin Anhydrous Gel In Microcystic Lymphatic Malformations; On Track To Submit NDA In H2 Of 2026

Palvella Therapeutics Receives U.S. Patent For Its Licensed QTORIN Pitavastatin Program For Porokeratosis

Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target

Palvella Therapeutics Presents New Clinical Data From Phase 3 SELVA And Phase 2 TOIVA Studies At ISSVA World Congress 2026

Palvella Therapeutics Presents New Data From Phase 2 TOIVA Trial Of QTORIN Rapamycin In Patients With Cutaneous Venous Malformations At Annual Meeting Of SID

Palvella Therapeutics Receives Approval To Uplist To Nasdaq Global Market

Stephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220

Palvella Therapeutics, Inc. (PVLA) Q1 2026 Earnings Call Transcript

Palvella Therapeutics (NASDAQ:PVLA) Reports Wider Q1 Loss but NDA Submission Stay on Track

Palvella Therapeutics Q1 EPS $(1.20) Misses $(0.93) Estimate

Palvella Announces First Patients Dosed In LOTU, Multicenter Phase 2 Clinical Trial To Evaluate Safety And Efficacy Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Clinically Significant Angiokeratomas

Palvella Therapeutics To Highlight Results From Phase 3 SELVA And Phase 2 TOIVA Studies Of QTORIN Rapamycin At ISSVA World Congress 2026

Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240

Palvella Therapeutics shares are trading higher. The company reported its Q4 financial results.

Palvella Therapeutics shares are trading higher. The company reported its Q4 financial results.

Palvella Therapeutics Q4 EPS $(1.08) Misses $(0.91) Estimate

Palvella Therapeutics Publishes Comprehensive Review Article Titled Microcystic and Macrocystic Lymphatic Malformations: Distinct Genetics And Clinical Strategies

HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Raises Price Target to $270

Palvella Therapeutics: A Potential First-In-Class Therapy In A Rare Dermatology Market

Palvella Therapeutics Secures European Patent Covering Lead QTORIN Rapamycin Gel